Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 1,508.9%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 2,600,000 shares, anincreaseof1,508.9% from the June 30th total of 161,600 shares. Based on an average daily trading volume, of 10,080,000 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily trading volume, of 10,080,000 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent SEC filing. 29.33% of the stock is currently owned by hedge funds and other institutional investors.

Windtree Therapeutics Price Performance

Shares of NASDAQ WINT opened at $0.60 on Friday. The stock’s fifty day moving average price is $0.73 and its two-hundred day moving average price is $2.44. Windtree Therapeutics has a one year low of $0.36 and a one year high of $737.44. The firm has a market cap of $2.20 million, a price-to-earnings ratio of 0.00 and a beta of 0.63.

Windtree Therapeutics (NASDAQ:WINT) last released its quarterly earnings results on Thursday, May 15th. The company reported ($4.63) EPS for the quarter, beating the consensus estimate of ($39.00) by $34.37. On average, equities analysts anticipate that Windtree Therapeutics will post -5.66 earnings per share for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.